(Webinar Held: January 27, 2021) Join HDA and The Hill for a virtual conversation between policymakers, leaders in the pharmaceutical and distribution industries and public health experts on how vaccines...
The 91st Edition HDA Factbook (2020–2021) provides comprehensive distribution performance metrics that highlight growth and trends in the pharmaceutical industry.
NON - MEMBER PRICE: $0.00 | MEMBER PRICE: $0.00
(Webinar held: March 26, 2021) COVID-19 continues to have a far-reaching effect on the nation's economy, including the pharmaceutical sector.
Developed in collaboration with Deloitte Consulting LLP, this report examines the role that the supply chain played in delivering medicines safely and efficiently to patients during the unprecedented early...
The 12th edition of the HDA Research Foundation’s annual benchmarking publication on specialty pharmaceuticals offers insight into this unique marketplace, and closely examines specialty distribution measures...
PRICE : $0.00 - $0.00
This new, interactive course is made up of 11 modules illustrating the key pharmaceutical supply chain stakeholders and their functions as products move from the manufacturer to the customer.
The fifth edition of the HDA Research Foundation's survey provides objective data on the current readiness of manufacturers and distributors to meet Drug Supply Chain Security Act (DSCSA) requirements.
This turnkey presentation includes an explanation of the specialty pharmaceutical supply chain players and a discussion on the economics of specialty pharmaceutical distribution.
Published in collaboration with Deloitte Consulting LLP, The Role of Distributors in the US Health Care Industry provides insights into the importance of wholesalers in driving efficiency and innovation...
PRICE : 0.00 - 0.00
Personalized medicine is a rapidly evolving and growing field. The shift from one-size-fits-all medicine to a more targeted, individualized approach has broad implications for the healthcare supply chain...
This report explores proposed drug importation policy — in general, and with an emphasis on federal legislation proposed since 2013.
Since 1992, the 340B Drug Pricing Program has played a modest, but increasingly important, role in the U.S. healthcare market.
